Quantifying the Benefits of Digital Biomarkers and Technology-Based Study Endpoints in Clinical Tria
- DHV-NET
- Oct 6, 2023
- 1 min read
Four scenarios with different combinations of technologies were illustrated. The model illustrated a way to quantify the magnitude of the contributions that enrichment and endpoint technologies could make to drug development studies.
